CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS).
about
Immune Mechanisms in Myelodysplastic SyndromeBeyond hypomethylating agents failure in patients with myelodysplastic syndromesImmunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumabDeregulation of innate immune and inflammatory signaling in myelodysplastic syndromesAcquired myelodysplasia or myelodysplastic syndrome: clearing the fogMyelodysplastic syndromes: the role of the immune system in pathogenesis.IPSS-independent prognostic value of plasma CXCL10, IL-7 and IL-6 levels in myelodysplastic syndromesThe relationship between idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and autoimmunity.CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.T-cell receptor Vβ skewing frequently occurs in refractory cytopenia of childhood and is associated with an expansion of effector cytotoxic T cells: a prospective study by EWOG-MDS.A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction.Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy.Aging-like phenotype and defective lineage specification in SIRT1-deleted hematopoietic stem and progenitor cellsCurrent therapy of myelodysplastic syndromesThe different immunoregulatory functions of mesenchymal stem cells in patients with low-risk or high-risk myelodysplastic syndromesPitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.Th22 cells as well as Th17 cells expand differentially in patients with early-stage and late-stage myelodysplastic syndrome.The different immunoregulatory functions on dendritic cells between mesenchymal stem cells derived from bone marrow of patients with low-risk or high-risk myelodysplastic syndromesT-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapyTreating myelodysplastic syndrome improves an accompanying autoimmune disease along with a reduction in regulatory T-cells.Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects.Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency.Immune derangements in patients with myelofibrosis: the role of Treg, Th17, and sIL2Rα.CD4+CD25highFoxP3+ regulatory T-cells in hematologic diseasesAltered naive and memory CD4+ T-cell homeostasis and immunosenescence characterize younger patients with myelodysplastic syndromeInterferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes.Biology of the bone marrow microenvironment and myelodysplastic syndromes.Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitroMyelodysplastic Syndrome Revealed by Systems Immunology in a Melanoma Patient Undergoing Anti-PD-1 TherapyMyelodysplastic syndromes and autoimmune diseases--case series and review of literatureThe effects of 5-azacytidine on the function and number of regulatory T cells and T-effectors in myelodysplastic syndromeThe Systemic Profile of Soluble Immune Mediators in Patients with Myelodysplastic Syndromes.Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance.Immune mediated autologous cytotoxicity against hematopoietic precursor cells in patients with myelodysplastic syndrome.Certain Autoimmune Manifestations Are Associated With Distinctive Karyotypes and Outcomes in Patients With Myelodysplastic Syndrome: A Retrospective Cohort Study.Th17 and Treg cells in bone related diseases.Th17 Cells Exhibit Antitumor Effects in MDS Possibly through Augmenting Functions of CD8+ T CellsPD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells.Specific plasma autoantibody reactivity in myelodysplastic syndromes.
P2860
Q26744500-0867199A-8F97-4112-B570-ABC10551F2C1Q26827079-C7649E45-BCE1-4D81-8426-512FEA2379FEQ26864200-6A77D12B-DA1D-447C-AA58-A1AB7E02A7AEQ27015288-51866BA9-FAC7-400B-9E3B-AE664E37A72CQ28662217-8750C599-37FF-432F-B38E-5C2229F50CBEQ33351527-BB870519-469D-4083-8FFE-252B4263DC51Q33397165-1AEEC309-4A4D-4D18-A7D2-E9FD15B41A01Q33442467-2EAA4D21-FC3A-4CFC-88C3-536FF7948656Q33585293-1CAF8453-C29A-4A3E-91E1-83CB1C494E65Q33657377-4EFDA127-3D21-499C-B3B6-C0707BF40342Q33702157-4E023F0F-5975-4FCD-A3F8-15A2AE40796AQ33828560-9E142C4E-CDB0-41DE-9E75-AD2CDF1CB60FQ33892358-BD89EE6E-6B00-4039-97E8-FA11CAEC575FQ33949133-3BE9237B-CF7D-4D60-BE61-B1FE8D51FC85Q34013796-16B2B3DF-776B-4E4C-9F8C-3986C331940AQ34429788-6B8DF154-664F-4492-9F34-B2E96612BCF3Q34508125-1A6592F1-4D9E-488A-A7B3-DEC6D13C9075Q34510880-B51FFAF6-89EC-45E4-B356-4269D3C447F4Q34613086-D85C3A80-6C5E-43A6-9467-9F0E105A96A9Q34707452-13D56F98-2E8D-471A-8BA5-AAC3F4860AA1Q34810444-51F1A2A1-FD57-4B87-8EF4-6B46C0C08419Q35033249-7B72EE5F-15DD-4B25-B030-3DFAE0F7B545Q35136851-0575B6E7-0026-4E53-9B84-2DEB62317F22Q35203067-3939DE56-8FAC-4661-92DC-5B835965C994Q35300172-562A358F-FB42-4B74-A74F-23027C07F08DQ35657367-B4D86C7D-4918-4DC4-B853-3757C5C3EA9CQ36031954-CA09048E-9DFD-4A0D-AD77-E4186E44165EQ36201068-411E716A-855D-455C-83AA-FE26B3AD7837Q36508920-857EF3E0-8802-44FC-A537-C7A5489A3645Q36963592-0EC23F63-6D51-4E70-88D2-3CBB0DFE297EQ36976674-7E799FDC-FF3F-479B-8CF3-3F47D901E555Q37060639-5AF91336-0B2B-4C77-BEC6-AED80BC543F3Q37134517-C4B42D2D-8267-4736-B1D8-F8BD2644A885Q37146019-99457B5B-3F2D-40AD-9177-8E68E70B0CADQ37146038-0C273BF0-CC29-4790-9C8A-FE7D02CCD1EFQ37205862-0F72D312-DD47-43CC-AC88-260C730A1840Q37239790-CE390BE6-1D3B-4982-BBEC-1EDBFEACD747Q37303329-6F306D80-7E4A-44ED-8862-0C4976B3D1D4Q37318142-9F512E2B-95C4-463E-9E7D-AB6AF4BFD66FQ37334237-220F72E4-7895-4BF6-BBA4-970C9B12DA53
P2860
CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS).
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS).
@en
CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome
@nl
type
label
CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS).
@en
CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome
@nl
prefLabel
CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS).
@en
CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome
@nl
P2093
P50
P1433
P1476
CD4+CD25high Foxp3+ regulatory T cells in myelodysplastic syndrome (MDS).
@en
P2093
David Darling
Ghulam J Mufti
Giovanna Lombardi
Janet Hayden
Jaroslaw P Maciejewski
Linda Barber
Wendy Ingram
P304
P356
10.1182/BLOOD-2007-01-067546
P407
P577
2007-04-05T00:00:00Z